Login / Signup

Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence.

Mateusz Jacek SpałekPaweł TeteryczAneta BorkowskaJan PoleszczukPiotr Rutkowski
Published in: Therapeutic advances in medical oncology (2022)
SRT provides excellent local control in STBS patients without significant toxicity. Patients with oligometastatic disease, lung metastases, and soft tissue sarcomas benefit the most from SRT. The dose escalation moderately enhances local control; however, it does not translate into better survival.
Keyphrases